BlackRock’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-679,323
| Closed | -$3.33M | – | 5932 |
|
|
2021
Q3 | $3.33M | Sell |
679,323
-4,016
| -0.6% | -$19.5K | ﹤0.01% | 4105 |
|
|
2021
Q2 | $3.61M | Buy |
683,339
+134,329
| +24% | +$695K | ﹤0.01% | 4015 |
|
|
2021
Q1 | $2.63M | Buy |
549,010
+14,097
| +3% | +$73.6K | ﹤0.01% | 4201 |
|
|
2020
Q4 | $2.32M | Buy |
534,913
+3,994
| +0.8% | +$17.1K | ﹤0.01% | 3990 |
|
|
2020
Q3 | $2.19M | Sell |
530,919
-67,151
| -11% | -$260K | ﹤0.01% | 3881 |
|
|
2020
Q2 | $1.53M | Sell |
598,070
-1,182,408
| -66% | -$3.47M | ﹤0.01% | 3907 |
|
|
2020
Q1 | $5.15M | Buy |
1,780,478
+45,169
| +3% | +$202K | ﹤0.01% | 3347 |
|
|
2019
Q4 | $6.58M | Sell |
1,735,309
-480,867
| -22% | -$2.3M | ﹤0.01% | 3430 |
|
|
2019
Q3 | $11.3M | Buy |
2,216,176
+21,088
| +1% | +$130K | ﹤0.01% | 3146 |
|
|
2019
Q2 | $13.6M | Buy |
2,195,088
+112,278
| +5% | +$646K | ﹤0.01% | 3063 |
|
|
2019
Q1 | $14.8M | Buy |
2,082,810
+18,052
| +0.9% | +$162K | ﹤0.01% | 2910 |
|
|
2018
Q4 | $17.6M | Buy |
2,064,758
+174,844
| +9% | +$2.27M | ﹤0.01% | 2792 |
|
|
2018
Q3 | $37.8M | Buy |
1,889,914
+43,818
| +2% | +$1.03M | ﹤0.01% | 2532 |
|
|
2018
Q2 | $47.7M | Buy |
1,846,096
+361,303
| +24% | +$10M | ﹤0.01% | 2381 |
|
|
2018
Q1 | $35.5M | Buy |
1,484,793
+139,385
| +10% | +$4.39M | ﹤0.01% | 2467 |
|
|
2017
Q4 | $45.6M | Sell |
1,345,408
-9,563
| -0.7% | -$267K | ﹤0.01% | 2346 |
|
|
2017
Q3 | $28.7M | Buy |
1,354,971
+165,930
| +14% | +$3.04M | ﹤0.01% | 2607 |
|
|
2017
Q2 | $20.8M | Sell |
1,189,041
-111,388
| -9% | -$1.84M | ﹤0.01% | 2768 |
|
|
2017
Q1 | $22.8M | Buy |
1,300,429
+1,297,729
| +48,064% | +$22.1M | ﹤0.01% | 2679 |
|
|
2016
Q4 | $46K | Sell |
2,700
-219
| -8% | -$3.39K | ﹤0.01% | 2979 |
|
|
2016
Q3 | $48K | Sell |
2,919
-945
| -24% | -$14.4K | ﹤0.01% | 2981 |
|
|
2016
Q2 | $59K | Buy |
3,864
+3,102
| +407% | +$51.1K | ﹤0.01% | 2855 |
|
|
2016
Q1 | $11K | Buy |
762
+459
| +151% | +$7.73K | ﹤0.01% | 3130 |
|
|
2015
Q4 | $9K | Hold |
303
| – | – | ﹤0.01% | 2947 |
|
|
2015
Q3 | $5K | Hold |
303
| – | – | ﹤0.01% | 3036 |
|
|
2015
Q2 | $8K | Buy |
+303
| New | +$5.89K | ﹤0.01% | 2939 |
|
|
2014
Q4 | – | Sell |
-21,100
| Closed | -$393K | – | 3200 |
|
|
2014
Q3 | $393K | Sell |
21,100
-1,700
| -7% | -$29.2K | ﹤0.01% | 1389 |
|
|
2014
Q2 | $417K | Buy |
+22,800
| New | +$408K | ﹤0.01% | 1362 |
|
BlackRock's ADMS Position: Q4 2021 in Review
BlackRock sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 679,323 shares — an estimated $3.33M sold.
BlackRock first reported a position in ADMS in Q2 2014 and held it in 28 quarters. The position peaked at $47.7M in Q2 2018. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- BlackRock reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- BlackRock sold 679,323 Adamas Pharmaceuticals shares in Q4 2021, an estimated $3.33M.
- BlackRock first reported a position in Adamas Pharmaceuticals in Q2 2014 and held it in 28 quarters.
- BlackRock's Adamas Pharmaceuticals position peaked at $47.7M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on BlackRock's 13F filing for Q4 2021, filed 10 Feb 2022.